Shares of Eli Lilly finished Thursday 3% higher despite an earnings report that showed sales of its blockbuster GLP-1 ...

Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its ...

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.

Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals that distract from ...

Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Long-Term Pick’s Substack by Dan. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S (NVO)’s share was trading ...

Novo Nordisk, maker of Ozempic and Wegovy ... The right-wing argues, as the Heritage Foundation's Project 2025 puts it, that government negotiations on Medicare drugs amount to "price controls" that ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

Finally, some good news for Novo Nordisk (NYSE: NVO) shareholders! Twice in the past two months, the Danish manufacturer of GLP-1 drugs for weight loss and diabetes treatment has reported clinical ...

Also Read: Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations ... Based on the results, Novo Nordisk is planning further clinical development of amycretin in ...

See the 10 stocks » However, the Centers for Medicare and Medicaid Services (CMS) could soon throw a monkey wrench into Novo Nordisk's momentum. The agency announced last week that Ozempic and ...